The Rheumatoid Arthritis Diagnostic Tests Market, estimated at USD 3,082.8 Mn in 2025, is expected to exhibit a CAGR of 5.4% and reach USD 4,454.8 Mn by 2032.
The market growth is driven by rising demand for accurate and early disease detection, supported by advances in molecular diagnostics, imaging, and point-of-care testing. Growing focus on personalized medicine, supportive healthcare policies, and ongoing R&D investments are creating new opportunities for industry players.
Key market players are focused on adopting growth strategies such as partnerships, which will drive the global rheumatoid arthritis diagnostic tests market. For instance, in September 2025, Ortho Clinical Diagnostics, pure-play in vitro diagnostics (IVD) companies, announced the availability of Immediate Spin Crossmatch (ISXM) on the company’s ortho vision and ortho vision max analyzers to aid in detecting incompatibility between donors and recipients in blood transfusions. serological test used in blood transfusions to detect ABO blood type incompatibility between donor red blood cells and recipient serum/plasma.
Global Rheumatoid Arthritis Diagnostic Tests Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regard to the transportation of thingss from one place to another.
COVID-19 had a positive impact on the global rheumatoid arthritis diagnostic tests market..For instance, in April 2025, Siemens Healthcare GmbH, formally unveiled the RAPIDPoint 500e Blood Gas Analyzer, adding to the company's product lineup and supporting COVID-19 initiatives. This is assisting in raising the revenue for the line.
Global Rheumatoid Arthritis Diagnostic Tests Market: Key Developments
In July 2025, Beckman Coulter, is a clinical diagnostics company, announced that it has entered into definitive agreements with Quidel Corporation to obtain all rights related to the manufacture, distribution, and sale of a BNP assay for Beckman Coulter analyzers. Under the terms of the agreements, Quidel will continue to manufacture and supply certain components to Beckman Coulter related to the assay, and Beckman Coulter will exclusively manufacture and sell to customers the BNP assay currently sold as TRIAGE BNP by Quidel, under the brand name Access BNP.
In May 2025, Leica Microsystems, is a microscope manufacturing company in Germany, has launched Stellaris, its new flagship confocal microscopy platform, designed to significantly improve how scientists are able to capture three-dimensional images of living cells and tissues. announced the launch of STELLARIS, the company's flagship platform for its ground-breaking confocal microscope. This platform enables three-dimensional viewing of live tissues and cells. For instance, in May 2025, F. Hoffmann-La Roche Ltd. is a multinational healthcare company in switzerland announced its acquisition of Stratos Genomics. The development of diagnostic sequencing based on DNA was made possible by this acquisition. This enhanced the business's healthcare diagnosing division and raised its revenue-generating capacity.